Ziv-aflibercept是Aflibercept的一种可溶性VEGF抑制剂变体，具有低pH和高渗透压的特性，在转移性结直肠癌和视网膜疾病中具有潜在应用价值。

[1] Malik D, Tarek M, Caceres del Carpio J, Ramirez C, Boyer D, Kenney MC, Kuppermann BD. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i11-16. doi: 10.1136/bjophthalmol-2014-305302. PMID: 24836865; PMCID: PMC4033208.[2]de Oliveira Dias JR, de Andrade GC, Novais EA, Farah ME, Rodrigues EB. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. Int J Retina Vitreous. 2016 Feb 1;2:3. doi: 10.1186/s40942-016-0026-y. PMID: 27847621; PMCID: PMC5088480.